Yahoo Search Búsqueda en la Web

  1. Anuncio

    relacionado con: Tetsuya Iida
  2. Find deals and low prices on tetsuya ishida at Amazon.com. Browse & discover thousands of brands. Read customer reviews & find best sellers

Resultado de búsqueda

  1. Profile. Dr. Iida graduated Faculty of Science, Kyoto University in 1984 and received his Ph.D. from Osaka university in 1991. He was appointed SA Professor at the International Research Center for Infectious Diseases in RIMD after working as a Research Associate for six years and an Associate Professor for seven years.

  2. Tetsuya Iida Vibrio parahaemolyticus is a Gram-negative pathogen that causes food-borne gastroenteritis. A major virulence determinant of the organism is a type III secretion system (T3SS2 ...

  3. Tetsuya Iida. Kyoto Prefectural University of Medicine: Kyoto, JP. 2019-04-01 to 2023-03-31 | MD, PhD (Graduate School of Medical Science) Education. Show more detail. Source : Tetsuya Iida.

  4. 21 de dic. de 2021 · Here, we employed direct RNA sequencing to annotate the Vibrio parahaemolyticus transcriptome with its full features, including transcription start sites (TSSs), transcription termination sites, and operon maps. A total of 4,103 TSSs were identified.

  5. Shota Nakamura 1 , Takaaki Nakaya , Tetsuya Iida. Affiliation. 1 Department of Infection Metagenomics, Genome Information Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan. PMID: 21737580. DOI: 10.1258/ebm.2011.010378. Abstract.

  6. Metagenomic analysis of diarrheal stools in Kolkata, India, indicates the possibility of subclinical infection of Vibrio cholerae O1. Eizo Takahashi, Daisuke Motooka, Shota Nakamura, Shin-ichi Miyoshi, Goutam Chowdhury, Asish K. Mukhopadhyay, Shanta Dutta, Daichi Morita, Tetsuya Iida, Keinosuke Okamoto.

  7. 5 de oct. de 2018 · Abstract. SCD1 is a rate-limiting enzyme in the conversion of saturated fatty acids to monounsaturated fatty acids. SCD1 inhibitors have potential effects on obesity, diabetes, acne, and cancer, but the adverse effects associated with SCD1 inhibition in the skin and eyelids are impediments to clinical development.